ALX Oncology Holdings Inc. (ALXO)
ALXO Stock Price Chart
Explore ALX Oncology Holdings Inc. interactive price chart. Choose custom timeframes to analyze ALXO price movements and trends.
ALXO Company Profile
Discover essential business fundamentals and corporate details for ALX Oncology Holdings Inc. (ALXO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Jul 2020
Employees
65.00
Website
https://www.alxoncology.comCEO
Jason W. Lettmann
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
ALXO Financial Timeline
Browse a chronological timeline of ALX Oncology Holdings Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.38.
Earnings released on 12 Aug 2025
EPS came in at -$0.49 falling short of the estimated -$0.46 by -6.52%.
Earnings released on 8 May 2025
EPS came in at -$0.58 falling short of the estimated -$0.47 by -23.40%.
Earnings released on 6 Mar 2025
EPS came in at -$0.55 surpassing the estimated -$0.72 by +23.61%.
Earnings released on 7 Nov 2024
EPS came in at -$0.58 surpassing the estimated -$0.78 by +25.64%.
Earnings released on 8 Aug 2024
EPS came in at -$0.76 surpassing the estimated -$0.77 by +1.30%.
Earnings released on 9 May 2024
EPS came in at -$0.71 surpassing the estimated -$0.87 by +18.39%.
Earnings released on 7 Mar 2024
EPS came in at -$0.93 falling short of the estimated -$0.84 by -10.71%, while revenue for the quarter reached $2.48M .
Earnings released on 13 Nov 2023
EPS came in at -$1.24 falling short of the estimated -$0.86 by -44.19%.
Earnings released on 10 Aug 2023
EPS came in at -$0.84 surpassing the estimated -$0.85 by +1.18%.
Earnings released on 11 May 2023
EPS came in at -$0.58 surpassing the estimated -$0.84 by +30.95%.
Earnings released on 9 Mar 2023
EPS came in at -$0.60 surpassing the estimated -$0.91 by +34.07%.
Earnings released on 8 Nov 2022
EPS came in at -$0.72 surpassing the estimated -$0.75 by +4.00%.
Earnings released on 8 Aug 2022
EPS came in at -$0.67 falling short of the estimated -$0.66 by -1.52%.
Earnings released on 9 May 2022
EPS came in at -$0.46 surpassing the estimated -$0.77 by +40.26%.
Earnings released on 28 Feb 2022
EPS came in at -$0.56 surpassing the estimated -$0.63 by +11.11%.
Earnings released on 11 Nov 2021
EPS came in at -$0.51 falling short of the estimated -$0.47 by -8.51%.
Earnings released on 12 Aug 2021
EPS came in at -$0.34 surpassing the estimated -$0.42 by +19.05%.
Earnings released on 17 May 2021
EPS came in at -$0.31 surpassing the estimated -$0.46 by +32.61%.
Earnings released on 18 Mar 2021
EPS came in at -$0.44 falling short of the estimated -$0.36 by -22.22%, while revenue for the quarter reached $1.18 .
Earnings released on 12 Nov 2020
EPS came in at -$0.32 surpassing the estimated -$0.37 by +13.51%.
ALXO Stock Performance
Access detailed ALXO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.